Compare Novartis AG (NVS) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Xylem, Inc. — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Xylem, Inc. trades at $120.79 (market cap $28.67B). The key difference: Novartis AG is far larger — about 10.1× Xylem, Inc.'s market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | XYL | |
|---|---|---|
Market Cap | $290.25B | $28.67B |
Sector | Health | Industrials |
52-Week High | $168.62 | $152.95 |
52-Week Low | $113.50 | $106.34 |
Enterprise Value | $330.27B | $29.92B |
Dividend Yield | 3.17% | 1.43% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
